US2004120897A1PendingUtilityA1
Method for administering insulinotropic peptides
Priority: Aug 28, 1998Filed: Dec 10, 2003Published: Jun 24, 2004
Est. expiryAug 28, 2018(expired)· nominal 20-yr term from priority
A61K 9/0073A61K 38/26
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The claimed invention relates to a method of administering glucagon-like peptide-1 molecules by inhalation, a method for treating diabetes by administering glucagon-like peptide-1 molecules by inhalation, and a method for treating hyperglycemia by administering glucagon-like peptide-1 molecules by inhalation.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A method of administering a glucagon-like peptide-1(GLP-1) molecule comprising, administering an effective amount of a GLP-1 molecule selected from the group consisting of GLP-1, GLP-1 analogs, or GLP-1 derivatives to a patient in need thereof by pulmonary means.
2 . The method of claim 1 , wherein the GLP-1 molecule is delivered to lower airwaya of the patient.
3 . The method of claim 2 , wherein the GLP-1 molecule is deposited in the alveoli.
4 . The method of claim-1, wherein the GLP-1 molecule is inhaled through the mouth of the patient.
5 . The method of claim 1 , wherein the GLP-1 molecule is administered as a pharmaceutical formulation comprising the GLP-1 molecule in a pharmaceutically acceptable carrier.
6 . The method of claim 5 , wherein the formulation is selected from the group consisting of a solution in an aqueous medium and a suspension in a non-aqueous medium.
7 . The method of claim 6 , wherein the formulation is administered as an aerosol.
8 . The method of claim 5 , wherein the formulation is in the form of a dry powder.
9 . The method of claim 5 , wherein the GLP-1 molecule has a particle size of less than about 10 microns MMAD.
10 . The method of claim 9 , wherein the GLP-1 molecule has a particle size of about 1 to about 5 microns MMAD.
11 . The method of claim 10 , wherein the GLP-1 molecule has a particle size of about 2 to about 3 microns MMAD.
12 . The method of claim 1 , wherein at least about 10% of the GLP-1 molecule delivered is deposited in the lung.
13 . The method of claim 1 , wherein the GLP-1 molecule is delivered from an inhalation device suitable for pulmonary administration and capable of depositing the GLP-1 molecule in the lungs of the patient.
14 . The method of claim 13 , wherein the device is selected from the group consisting of a nebulizer, a metered-dose inhaler, a dry powder inhaler, and a sprayer.
15 . The method of claim 14 , wherein the device is a dry powder inhaler.
16 . The method of claim 1 wherein the GLP-1 molecule is selected from the group consisting of GLP-1 analogs and GLP-1 derivatives.
17 . The method of claim 16 wherein the GLP-1 molecule is a GLP-1 analog.
18 . The method of claim 17 wherein the GLP-1 analog is selected from the group consisting of Val 8 -GLP-1(7-37)OH, Gly 8 -GLP-1 (7-37)OH, and Asp 8 -GLP-1 (7-37)OH.
19 . The method of claim 18 , wherein the GLP-1 analog is Val 8 -GLP-1 (7-37) OH.
20 . The method of claim 18 , wherein the GLP-1 analog is Gly 8 -GLP-1 (7-37)OH.
21 . A method for treating diabetes comprising, administering an effective dose of a GLP-1 molecule to a patient in need thereof by pulmonary delivery.
22 . The method of claim 21 , wherein the GLP-1 molecule is administered as a pharmaceutical formulation comprising the GLP-1 molecule in a pharmaceutically acceptable carrier.
23 . The method of claim 21 , wherein the GLP-1 molecule is Val 8 -GLP-1 (7-37)OH.
24 . The method of claim 21 , wherein the GLP-1 molecule is Gly 8 -GLP-1 (7-37)OH.
25 . The method of claim 21 , wherein the GLP-1 molecule is delivered from an inhalation device suitable for pulmonary administration and capable of depositing the GLP-1 molecule in the lungs of the patient.
26 . The method of claim 25 , wherein the device is a sprayer or a dry powder inhaler.
27 . The method of claim 25 , wherein an actuation of the device administers about 40 μg to about 4,000 μg of a GLP-1 molecule.
28 . The method of claim 25 , wherein an actuation of the device administers about 80 μg to about 2,000 μg of a GLP-1 molecule.
29 . The method of claim 25 , wherein an actuation of the device administers about 160 μg to about 1,000 μg of a GLP-1 molecule.
30 . The method of claim 25 , wherein an actuation of the device administers about 320 μg to about 500 μg of a GLP-1 molecule.
31 . A method for treating hyperglycemia comprising, administering an effective dose of a GLP-1 molecule to a patient in need thereof by pulmonary means.
32 . The method of claim 31 , wherein the GLP-1 molecule is administered as a pharmaceutical formulation comprising the GLP-1 molecule in a pharmaceutically acceptable carrier.
33 . The method of claim 31 , wherein the GLP-1 molecule is Val 8 -GLP-1 (7-37)OH.
34 . The method of claim 31 , wherein the GLP-1 molecule is Gly 8 -GLP-1 (7-37) OH.
35 . The method of claim 31 , wherein the GLP-1 molecule is delivered from an inhalation device suitable for pulmonary administration and capable of depositing the GLP-1 molecule in the lungs of the patient.
36 . The method of claim 35 , wherein the device is selected from the group consisting of a sprayer and a dry powder inhaler.
37 . The method of claim 35 , wherein an actuation of the device administers about 40 μg to about 4,000 μg of GLP-1 molecule.
38 . The method of claim 35 , wherein an actuation of the device administers about 8.0 μg to about 2,000 μg of the GLP-1 molecule.
39 . The method of claim 35 , wherein an actuation of the device administers about 160 μg to about 1,000 μg of GLP-1 molecule.
40 . The method of claim 35 , wherein an actuation of the device administers about 320 μg to about 500 μg of the GLP-1 molecule.Join the waitlist — get patent alerts
Track US2004120897A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.